Pentosan Polysulfate Treatment's Effectiveness

Chronic Interstitial Cystitis Clinical Trial

Official title:

Retrospective Evaluation of the Effectiveness of Oral Pentosan Polysulfate Treatment in the Improvement of Chronic Interstitial Cystitis Symptoms.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05744908
• Other study ID #: 10.01.2023/37
• Status: Completed
• Phase: N/A
• Start date: January 1, 2018
• Est. completion date: January 10, 2023

Study information

• Verified date: February 2023
• Source: Hisar Intercontinental Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).

Description:

Demographic characteristics, medical history, clinical conditions, and laboratory and cystoscopic data of patients who applied to our clinic between January 2018 and December 2021 and were diagnosed with IC/BPS were retrospectively analyzed. Adult male and female patients with IC/BPS who received 300 mg/day PPS at least six months ago with complaints of pain, urge, frequency, and nocturia not associated with urinary tract infection were included in the study. In addition, pre- and post-treatment symptoms, ICSI scores, quality of life (scored between 1-4), and satisfaction were compared.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: January 10, 2023
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Chronic interstitial cystitis
• Bladder Pain Syndrome

Exclusion Criteria:

• Acute cystitis
• Bladder cancer
• Chronic prostatitis
• Bladder stone
• Stress incontinence

Related Conditions & MeSH terms

• Chronic Interstitial Cystitis
• Cystitis
• Cystitis, Interstitial

Intervention

Other:
• Pentosan Polysulphate
300mg 3 times a day

Locations

Country	Name	City	State
Turkey	Basri Cakiroglu	Istanbul
Turkey	Hisar Intercontinental Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Hisar Intercontinental Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bladder wall thickness	0.3 over 3 mm 1 under 3 mm,	Three months
Primary	improvement of lower urinary tract symptoms	1 if symptoms improved, 0 if not	Three months